LYONDELLBASELL ($LYB) – CYCLICAL GIANT OR UNDERRATED VALUE PLAY?
LYONDELLBASELL (
LYB) – CYCLICAL GIANT OR UNDERRATED VALUE PLAY?
(1/8)
Chemicals and timing can be like mixing reactive compounds—💥 one slip, and it all blows up! Let’s dissect howLYB fared in Q3 and see if it’s a hidden gem or just a lab experiment gone wrong.
(2/8)
Revenue & Earnings
Q3 revenue: 10.32B (vs. 10.60B estimated)
EPS: $1.75 (missed $1.88 forecast)
Net income: 573M (down from 747M in Q3 2023)
Take: These numbers show the sector’s cyclical nature—📉 butLYB’s not down for the count just yet.
(3/8)
Strategic Moves
Divested Ethylene Oxide & Derivatives (EO&D) to focus on higher-margin plays
Investments in advanced recycling & circular polymers (♻️) positionLYB for a sustainable future
Raised dividend by 5%—marking 13 years of annual dividend growth 💰
(4/8)
Sector Comparison
Some valuation models suggestLYB is 60.2% below fair value 🤔
Competitors: Dow Inc. & Eastman Chemical also face commodity price swings
LYB’s pivot to greener products might give it an edge if the market turns bullish
(5/8)
Cyclical Headwinds
Oil & gas volatility → Directly impacts production costs 🏭
Supply chain disruptions ⛓️
Global economic factors can tighten or loosen demand
Sustainability regs → both a cost & an opportunity 🌱
(6/8)
Risk Assessment
Debt Levels: Manageable, but higher rates could apply pressure
Regulatory Risks: Environmental standards tightening could require more capex ⚠️
Undervaluation Trap? A cheap stock can stay cheap if the market remains skeptical
(7/8)
My Analysis
“LYB’s shift toward circular polymers isn’t a gimmick—it’s a strategic bet that can pay off long-term. But remember, chemical stocks often swing wildly with macro cycles. If you can stomach the roller coaster, this could be a compelling play.”
(8/8)
Are you bullish onLYB?
🚀 Yes (Undervalued, strong dividend)
🤔 Neutral (Cyclical but stable)
🔥 No (Too risky given commodity and macro factors)
LYB) – CYCLICAL GIANT OR UNDERRATED VALUE PLAY?(1/8)
Chemicals and timing can be like mixing reactive compounds—💥 one slip, and it all blows up! Let’s dissect how
LYB fared in Q3 and see if it’s a hidden gem or just a lab experiment gone wrong.(2/8)
Revenue & Earnings
Q3 revenue: 10.32B (vs. 10.60B estimated)
EPS: $1.75 (missed $1.88 forecast)
Net income: 573M (down from 747M in Q3 2023)
Take: These numbers show the sector’s cyclical nature—📉 but
LYB’s not down for the count just yet.(3/8)
Strategic Moves
Divested Ethylene Oxide & Derivatives (EO&D) to focus on higher-margin plays
Investments in advanced recycling & circular polymers (♻️) position
LYB for a sustainable futureRaised dividend by 5%—marking 13 years of annual dividend growth 💰
(4/8)
Sector Comparison
Some valuation models suggest
LYB is 60.2% below fair value 🤔Competitors: Dow Inc. & Eastman Chemical also face commodity price swings
LYB’s pivot to greener products might give it an edge if the market turns bullish(5/8)
Cyclical Headwinds
Oil & gas volatility → Directly impacts production costs 🏭
Supply chain disruptions ⛓️
Global economic factors can tighten or loosen demand
Sustainability regs → both a cost & an opportunity 🌱
(6/8)
Risk Assessment
Debt Levels: Manageable, but higher rates could apply pressure
Regulatory Risks: Environmental standards tightening could require more capex ⚠️
Undervaluation Trap? A cheap stock can stay cheap if the market remains skeptical
(7/8)
My Analysis
“
LYB’s shift toward circular polymers isn’t a gimmick—it’s a strategic bet that can pay off long-term. But remember, chemical stocks often swing wildly with macro cycles. If you can stomach the roller coaster, this could be a compelling play.”(8/8)
Are you bullish on
LYB?🚀 Yes (Undervalued, strong dividend)
🤔 Neutral (Cyclical but stable)
🔥 No (Too risky given commodity and macro factors)
🔵 Gain access to our powerful tools 🛠️ : DCAlpha.net
All scripts & content provided by DCAChampion are for informational & educational purposes only.
All scripts & content provided by DCAChampion are for informational & educational purposes only.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.